Supernus Pharmaceuticals
SUPN
275 hedge funds and large institutions have $2.03B invested in Supernus Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 92 increasing their positions, 111 reducing their positions, and 27 closing their positions.
44% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 27
4.01% more ownership
Funds ownership: 96.27% → 100.27% (+4%)
3% more funds holding
Funds holding: 266 → 275 (+9)
2% less capital invested
Capital invested by funds: $2.07B → $2.03B (-$38.7M)
17% less repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 111
36% less call options, than puts
Call options by funds: $6.34M | Put options by funds: $9.84M
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$42.8M |
| 2 |
Millennium Management
New York
|
+$22.8M |
| 3 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$20.9M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$17.4M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$15.2M |
| 2 |
TA
Teachers Advisors
New York
|
-$15.2M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$13.1M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$10.6M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$10.5M |
SUPN Hedge Fund Activity: Q3 2017 in Review
275 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2017, worth a combined $2.03B — down 1.9% from $2.07B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new SUPN positions and 27 closed out — a net gain of 12 holders — while 92 added to existing stakes and 111 trimmed.
The largest buyer was Vanguard Group, adding an estimated $42.8M. The largest seller was Glenmede Trust, cutting an estimated $15.2M.
- 275 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2017, up from 266 in Q2 2017.
- Funds reported $2.03B of Supernus Pharmaceuticals stock for Q3 2017, down 1.9% quarter-over-quarter.
- 39 funds opened new Supernus Pharmaceuticals positions in Q3 2017 and 27 closed out, a net change of +12 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2017 was Vanguard Group, an estimated $42.8M added.
- The largest Supernus Pharmaceuticals seller in Q3 2017 was Glenmede Trust, an estimated $15.2M sold.
Based on aggregated 13F filings for Q3 2017.